The Implications of AREDS 2 for Your Practice

macuhealth eye supplements

macuhealth eye supplementsFollowing the recent publication of the long-awaited AREDS 2 study, MacuHealth LLC is delighted to have its stated view endorsed, namely that supplementation with ALL THREE MACULAR CAROTENOIDS represents the best means of preventing progression of age-related macular degeneration (AMD).

It is now clear, scientifically documented and beyond dispute that:

1. AREDS 2 has demonstrated that the inclusion of macular carotenoids results in risk reduction for progression of AMD in subjects with poor dietary intake of the macular carotenoids, and that a supplement should not contain beta-carotene because of the risk of lung cancer and because this compound reduces bioavailability of circulating macular carotenoids. Taken together with the known superiority of a formulation containing all three macular carotenoids, including the centrally dominant carotenoid meso-zeaxanthin (MZ), in terms of increasing macular pigment and in terms of improving visual function, the observed benefit of supplemental macular carotenoids in AREDS 2 will be optimized using a formulation that contains lutein (L), zeaxanthin (Z) and MZ in a (mg) ratio of 10:10:2 (i.e. MacuHealth LMZ3).

2. Meso-zeaxanthin, which represents over 30% of macular pigment:

  •  Is proven to be the most potent antioxidant in the macula;1
  • Was not part of the AREDS II study;
  •  The combination of L, Z and MZ is required to exert maximal collective antioxidant effect of these compounds, as their respectivelyantioxidant capacities are interactively additive.2

3. AREDS 2 has confirmed the findings of other studies by once again demonstrating that beta-carotene is associated with increased risk of lung cancer amongst smokers, and the study investigators recommend that this compound should not be used in a supplement designed to protect against AMD.3 Furthermore, beta-carotene was shown to be associated with reduced serum bioavailability of circulating macular carotenoids, probably because of competition for of absorption in the gastrointestinal tract.

4. AREDS 2 reported no beneficial effects of Omega-3 fatty acids (DHA/EPA) for treatment of AMD.

5. It is not the case that all formulations containing L, Z and/or MZ, are the same in either claimed content or in terms of stability of constituent compounds. For example, a powder-based formula oxidizes quickly, thereby degrading the carotenoids.

6. A supplement containing 10 mg of lutein, 2 mg of zeaxanthin and 10 mg of meso-zeaxanthin is the ONLY formula to have demonstrated dramatic and rapid rises in macular pigment levels and consequential improvements in visual function.4


1 Li Bernstein
2 Li Bernstein

2 thoughts on “The Implications of AREDS 2 for Your Practice

  1. I work for Eye Solutions telling people about Macuhealth and signing them up to help turn their AMD around or at least slow it down, but as a senior with it in my family, I take it so as not to develop AMD. I recomment everyone that knows it is in their family, take it to keep from ever showing signs of this devastating cause of blindness.

    1. Hello Gyla. Thanks for reading. Glad to hear your taking preventative measures! Eyesight is one of our most precious gifts- why gamble with it? Knowing your family history, eating right and supplementing early are KEY in warding off AMD… You’re doing everything right thus far, Gyla! Please keep us updated on your progress!

Leave a Reply